Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010

Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010

The extraordinary general meeting resolved to approve the board's resolution on
14 March 2010 to raise a convertible loan of not more than SEK 111,150,000 by
issuing convertible bonds to Novo A/S.

In light of the convertible bond issue, the extraordinary general resolved to
elect Michael Shalmi from Novo A/S as new board member, instead of Johan
Christenson who was discharged, until the end of the next annual general
meeting. It was further resolved that the election and discharge shall become
effective when Novo A/S's acquisition of shares corresponding to 10.7 per cent
of the total number of shares and votes in Orexo has been completed.


For further information, contact: 
Torbjörn Bjerke, President and CEO 
Tel: +46 (0)708-66 19 90 
E-mail: torbjorn.bjerke@orexo.com 

Claes Wenthzel, Executive Vice President and CFO 
Tel: +46 (0)708-62 01 22 
E-mail: claes.wenthzel@orexo.com 


About Orexo
Orexo is a revenue generating pharmaceutical company focusing on developing
treatments for pain and inflammation. The company has four products on the
market as well as a broad project portfolio in late stages of development. Sales
and product development are mainly carried out through worldwide partnership
agreements with larger pharmaceutical companies. Abstral for the treatment of
break through cancer pain is currently Orexo's most important product. Abstral
was launched in major European countries in 2009 and is in registration phase in
the USA and in Japan.  Orexo has 108 employees, and has its head office located
in Uppsala, Sweden. More information can be found at www.orexo.com.


This is information that Orexo AB (publ) is required to disclose pursuant to the
Swedish Securities Markets Act. The information was provided for public release
on 31 March 2010 at 13:00 CEST.